Many patients need long-term corticosteroid use to manage their medical condition, hence risk side effects that become more common with cumulative dose (e.g., fractures, glaucoma). Others are at particularly high risk for severe side effects (e.g., hyperglycemia in diabetics, fractures and others in the elderly). Sparrow will develop safer next-generation corticosteroids for those patients. We have exclusive, global rights to an investigational drug that, when combined with a corticosteroid, will create products with potent anti-inflammatory efficacy and reduced side effect risk.



Phase 1

Phase 2

Phase 3

Development Plan



Inhaled, Injected, Intravenous, Ophthalmic, Topical

Internal or Partnerships

copyright (c) 2020 Sparrow Pharmaceuticals, Inc.